作用于过氧化物酶体增殖物激活受体药物的研究进展

Progresses on Drugs Targeting Peroxisome Proliferator-activated Receptors

过氧化物酶体增殖物激活受体(peroxisome proliferator-activated receptors,PPARs)是被脂肪酸等内源性配体、外源性过氧化物酶体增殖剂(peroxisome proliferators,PP)激活,进而调控参与脂类代谢某些酶基因表达的转录调节因子。PPARs与糖脂代谢性疾病、炎症及某些肿瘤的发生发展密切相关。PPARs激动剂和其部分激动剂主要用于治疗糖尿病,另外其拮抗剂同其一样也用于炎症和肿瘤的治疗。现就作用于PPARs药物的研究进展进行了综述。

Peroxisome proliferator-activated receptors（PPARs） are ligand-activated transcription factors, which can be activated by endogenous ligand just as fatty acid and exogenous ligand like peroxisome proliferators,and then regulated some enzymes expression which involved in lipid metabolism. PPARs are closely related to the glucolipid metabolic disease, inflammation, and the development of some tumors. PPARs agonists and partial agonsists are mainly used for the treatment of diabetes, but their antagonists are also used for inflammation and tumors. The review aims to Progresses on the PPARs drug＇s research are summarized.